Invesco Ltd. Raises Position in LivaNova PLC $LIVN

Invesco Ltd. lifted its stake in LivaNova PLC (NASDAQ:LIVN) by 13.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 126,266 shares of the company’s stock after acquiring an additional 14,892 shares during the quarter. Invesco Ltd. owned 0.23% of LivaNova worth $4,960,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. Central Pacific Bank Trust Division grew its position in LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company’s stock valued at $173,000 after buying an additional 290 shares during the period. CWM LLC boosted its position in shares of LivaNova by 52.3% in the first quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after purchasing an additional 299 shares during the period. Mariner LLC boosted its position in shares of LivaNova by 8.4% in the fourth quarter. Mariner LLC now owns 5,741 shares of the company’s stock worth $266,000 after purchasing an additional 446 shares during the period. DekaBank Deutsche Girozentrale boosted its position in shares of LivaNova by 2.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company’s stock worth $817,000 after acquiring an additional 500 shares during the last quarter. Finally, UMB Bank n.a. boosted its position in shares of LivaNova by 340.5% during the first quarter. UMB Bank n.a. now owns 837 shares of the company’s stock worth $33,000 after acquiring an additional 647 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on LIVN shares. Wolfe Research upgraded shares of LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a research report on Tuesday, May 20th. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Robert W. Baird upped their target price on shares of LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of LivaNova in a research report on Tuesday, May 13th. Finally, Barclays upped their price target on shares of LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, LivaNova presently has an average rating of “Buy” and an average price target of $59.71.

LivaNova Stock Performance

Shares of LIVN opened at $56.49 on Thursday. The stock has a 50 day moving average price of $47.11 and a 200 day moving average price of $43.24. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $3.08 billion, a price-to-earnings ratio of -14.52 and a beta of 0.92. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $57.35.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.21. The firm had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.93 earnings per share. Research analysts predict that LivaNova PLC will post 2.85 EPS for the current fiscal year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.